22nd Century Group (Nasdaq: XXII) to Participate in March 2023 Roth Investor Conference

Rhea-AI Summary

22nd Century Group (Nasdaq: XXII) will participate in one-on-one meetings at the 35th Annual Roth Conference from March 12-14, 2023, in Orange County, California. This leading biotechnology company focuses on reduced nicotine tobacco and advanced plant technologies. Investors interested in meetings can contact their Roth representative or reach out to Matt Kreps at mkreps@xxiicentury.com.

22nd Century has pioneered proprietary reduced nicotine content tobacco and received the first FDA MRTP authorization for a combustible cigarette in December 2021, emphasizing its commitment to tobacco harm reduction.

BUFFALO, N.Y., March 02, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced that the Company will be participating in one-on-one meetings during the 35^th Annual Roth Conference, to be held March 12-14, 2023 in Orange County, California.

Investors and attendees that would like to schedule a meeting with 22nd Century’s management can contact their Roth representative to arrange a meeting, or Matt Kreps, 22nd Century Investor Relations, at mkreps@xxiicentury.com.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading biotechnology company focused on utilizing advanced alkaloid plant technologies to improve health and wellness through tobacco harm reduction, reduced nicotine tobacco, hemp/cannabis and hops. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

Learn more about VLN^® at tryvln.com.

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

FAQ

When is the 35th Annual Roth Conference that 22nd Century Group will attend?

The 35th Annual Roth Conference will be held from March 12-14, 2023.

What is 22nd Century Group's focus in biotechnology?

22nd Century Group focuses on improved health through reduced nicotine tobacco, hemp/cannabis, and advanced plant technologies.

How can investors schedule a meeting with 22nd Century Group's management during the conference?

Investors can contact their Roth representative or email Matt Kreps at mkreps@xxiicentury.com.

What significant FDA authorization did 22nd Century Group receive?

22nd Century Group received the first FDA MRTP authorization for a combustible cigarette in December 2021.

What innovative products does 22nd Century Group offer?

22nd Century Group offers proprietary reduced nicotine content (RNC) tobacco plants and cigarettes.